# A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

> **NCT07327281** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Hyperglycemia

## Interventions

- **DRUG:** TQF3250 placebo
- **DRUG:** TQF3250 capsule

## Key facts

- **NCT ID:** NCT07327281
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327281, "A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07327281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*